

**Comparative Study between the Effects of
Angiotensin-Converting Enzyme Inhibitors and Beta
Blockers on Left Ventricular Function and Geometry
in Mild Hypertensive Patients**

Thesis

**Submitted for Partial Fulfillment of
Master Degree in Cardiology**

By

Ashraf Moussa Abdallah

M.B, B.CH

Supervisors

**Hussein Hassan Rizk, MD
Professor of Cardiology**

**Wafaa Anwar El Aroussy, MD
Professor of Cardiology**

**Magdy Mustafa Mokhtar, MD
Professor of Cardiology**

**Faculty of Medicine
Cairo University**

2007

ACKNOWLEDGMENT

Thanks to Allah who allowed me to accomplish this work.

I wish to thank deeply and sincerely and to express my gratitude to my professor and supervisor **Dr. Hussein Rizk**, Professor of Cardiology, Faculty of Medicine, Cairo University, for his close continuous guidance, following up and perceptive suggestions throughout the course of this study and for the valuable criticism and knowledge given and interest shown in all aspects of this work.

I'm very grateful to my professor and supervisor **Dr. Wafaa El Aroussy**, Professor of Cardiology, Faculty of Medicine, Cairo University for her kind help and for the expert guidance throughout this work.

Great thanks to **Dr. Magdy Mokhtar**, Professor of Cardiology, faculty of Medicine, Cairo University for his kind help and continuous advice in following details of this work.

Abstract

Background: Hypertension is a leading non-communicable disease and the most prevalent cardiovascular disease. Adaptation of the left ventricle to systemic hypertension is complex and it is characterized by functional and structural changes. Increased LV mass is a recognized complication of systemic hypertension and has been shown to be an important predictor of cardiovascular morbidity and mortality. The current study was undertaken to determine whether antihypertensive therapy reduce LVM, and whether these changes are accompanied by improved diastolic function. **Methods:** 60 patients (pts.) with mild hypertension were divided into two groups: Group (I) included 30 pts. who received ACE inhibitors; 15 pts. received Ramipril 5-10 mg once daily, and constituted subgroup Ia, and 15 pts. received Fosinopril 20 mg once daily, and constituted subgroup Ib. Group (II) included 30 pts. who received beta blockers (BB); 15 pts. received Atenolol 50-100 mg once daily, and constituted subgroup IIa, and 15 pts. received Metoprolol 100 mg once daily, and constituted subgroup IIb. Twenty healthy volunteers comprised a control group. To assess the effects of antihypertensive therapy on the heart; LVM, systolic and diastolic function, by M-mode, 2-D and pulsed wave Doppler echocardiography were evaluated. Echocardiographic examinations were performed before therapy, after 2 weeks from the start of therapy and at 2, 4 and 6 months intervals. **Results:** At baseline, there were 13 pts. with LVH in a ratio 21.6% of total hypertensive pts. while the rest of the hypertensive pts., 47 pts (78.4%), had normal geometric pattern. The concentric LVH was the predominant form (53.8%) followed by eccentric LVH (30.7%) and finally concentric remodeling (15.3%). Indices of systolic function in studied pts. were normal while indices of LV diastolic filling were significantly abnormal in pts. with hypertensive LVH compared to control. After therapy, normalization of blood pressure was achieved in all hypertensive patients. A significant reduction of LVM, RWT and improvement of LV diastolic filling was observed earlier with ACE inhibitors than with beta-blockers. Of particular interest was the fact that improvement in diastolic performance appeared earlier, and was preceded regression of LVM. **Conclusion:** 1-Therapy with ACEI and BB results in prevention/ regression of development of LVH in hypertensive patients. 2-The regression of LVM, LVMI, RWT and the improvement of LV diastolic function appears more evident and earlier with ACEI therapy than with BB therapy. 3-Improvement of LV diastolic function appears earlier, preceding the regression of LVH.

Key words: hypertension + LVH + ACE inhibitors +beta blockers.

Content

List of abbreviation.....	i
List of Tables.....	v
List of Figures.....	vii
INTRODUCTION	xiv
AIM OF THE WORK.....	xviii
REVIEW OF LITERATURE.....	
Chapter I: Definition, Hemodynamic and Pathophysiology of Hypertension.....	1
Chapter II: Cardiac involvement in hypertension.....	15
Chapter III: Goal of therapy in hypertension.....	69
Chapter IV: Echocardiographic evaluation of cardiac structure and function in hypertensive patients.....	92
METHODOLOGY.....	110
RESULTS.....	122
DISCUSSION.....	184
CONCLUSION.....	197
RECOMMENDATION.....	198
SUMMARY.....	199
REFERENCES.....	208
ARABIC SUMMARY.....	

List of abbreviation

% FS:	Percent fractional shortening.
ABPM:	Ambulatory blood pressure monitoring.
ACE:	Angiotensin-converting enzyme.
Angiotensin II:	Angiotensin II.
AR :	Pulmonary venous peak atrial contraction reversed velocity.
ASE:	American Society of echocardiography.
AT1RBAs:	Angiotensin II type I receptor blocking agents.
A-velocity:	Peak-filling velocity in atrial systolic phase.
AVP:	Arginine vasopressin.
BB:	Beta Blockers.
BP:	Blood pressure.
CHD:	Coronary heart disease.
CHF:	Congestive heart failure.
CNS:	Central nervous system.
CO:	Cardiac output.
CT:	Computed axial tomography.
CV:	Cardiovascular.
DT :	Early left ventricular filling deceleration time.

E/A :	The ratio of early to late peak filling velocity.
ECG:	Electrocardiogram.
ECX:	Extracellular matrix.
EDRF:	Endothelium-derived relaxing factor.
EDV:	End diastolic volume.
EF:	Ejection fraction.
EPSS:	E-Point septal separation.
ESV:	End systolic volume.
E-Velocity:	Early peak filling velocity.
HR:	Heart rate.
IVRT:	Isovolumic relaxation time.
IVSd:	Interventricular septal thickness at end diastole.
IVSs:	Interventricular septal thickness at end systole.
JNC:	Joint National Committee.
LV:	Left ventricle.
LVH:	Left ventricular hypertrophy.
LVIDd:	Left ventricular internal dimension diastole.
LVIDs:	Left ventricular internal dimension at systole.
LVM:	Left ventricular mass.

LVMI:	Left ventricular mass index.
MI:	Myocardial infarction.
MRI:	Magnetic resonance imaging.
NHP:	Egyptian National Hypertension Project.
NO:	Nitric Oxide.
NYHA:	New York Heart Association.
PNS:	Peripheral nervous system.
PVR:	Peripheral vascular resistance.
PWTd:	Posterior wall thickness at diastole.
PWTs:	Posterior wall thickness at systole.
RAAS:	Renin-angiotensin-aldosterone system.
RWT:	Relative wall thickness.
S/D:	Systolic-to-diastolic pulmonary venous flow ratio.
SPECT:	Single-photon emission computed tomography.
TOD:	Target organ damage.
WHO-ISH:	World Health Organization-International Society of Hypertension.

List of Tables

- Table 1: Stages of Blood Pressure Elevation and Hypertension.
- Table 2: Characteristics and functions of AT1 and AT2 receptors.
- Table 3: Differences between pathological and physiological LVH.
- Table 4: Hemodynamic and echocardiographic characteristics of different patterns of LVH.
- Table 5: Stages of diastolic dysfunction.
- Table.6: Shows the characteristics of LV geometry in systolic and diastolic dysfunction.
- Table 7: Shows the number, age, height, gender and the duration of hypertension of group I, group II and group III respectively.
- Table 8: Comparison between control group (group III) and ACEI group (group I) before treatment regarding echocardiographic findings.
- Table 9: Comparison between control group (group III) and BB group (groupII) before treatment regarding echocardiographic findings.
- Table 10: Comparison between ACEI group (group I) and BB group (group II) before treatment regarding echocardiographic findings.
- Table 11: Comparison between control group (group III) and ACEI group (group I) after treatment regarding

echocardiographic findings.

Table 12: Comparison between control group (group III) and BB group (group II) after treatment regarding echocardiographic findings.

Table 13: Comparison between ACEI group (group I) and BB group (group II) after treatment regarding echocardiographic findings.

Table 14: Comparison between Ramipril subgroup (Ia) before and after treatment regarding echocardiographic findings.

Table 15: Comparison between Fosinopril subgroup (Ib) before and after treatment regarding echocardiographic findings

Table 16: Comparison between Atenolol subgroup (IIa) before and after treatment regarding echocardiographic findings.

Table 17: Comparison between Metoprolol subgroup (IIb) before and after treatment regarding echocardiographic findings.

List of Figures

- Figure 1: *Wall stress and tension in a thin walled tube or chamber (Laplace's law).*
- Figure 2: Shows scheme of the renin-angiotensin mechanism indicating the site of action of angiotensin II type I receptor antagonist.
- Figure 3: Shows schematic depicting how the RAAS works. Here, activation of the RAAS is initiated by a low perfusion pressure in the juxtaglomerular apparatus.
- Figure 4: Shows an imbalance between these pressor and depressor actions of insulin may result in elevated blood pressure.
- Figure 5: Shows the prevalence of left ventricular hypertrophy by Echocardiography by age and sex in Framingham study.
- Figure 6: Shows pathogenesis of left ventricular hypertrophy
- Figure 7: Shows the pathogenic factors and consequences of left ventricular hypertrophy
- Figure 8: Shows that obesity produces eccentric LVH while hypertension produces concentric LVH.
- Figure 9: Shows that concentric LVH is seen in hypertension; the addition of sarcomeres in parallel results in wall thickening at the expense of chamber volume. eccentric LVH is defined by chamber dilatation and wall thickening. Sarcomeres are added in series as well as in parallel.

- Figure 10: Shows LVH is adaptation or a disease?
- Figure.11: Shows M mode echocardiogram recorded within the left ventricle, just below the level of the mitral valve annulus.
- Figure 12: Shows left ventricular geometrical patterns.
- Figure 13: Shows cardiovascular events in men and women in the Framingham Study according to left ventricular mass determined by echocardiography.
- Figure 14: Shows the diagram of left ventricular pump performance. The input is the pulmonary venous pressure, and the output is the cardiac output.
- Figure 15: Shows the consequences of systolic and diastolic dysfunction related hypertension.
- Figure 16: Shows the left ventricular (LV) pressure (PLV), left atrial pressure (PLA), left ventricular volume (LVV), and the rate of change of LV volume (dV/dt), which indicates the rate of LV filling.
- Figure 17: Shows the measurement of Doppler transmitral indexes of diastolic function
- Figure 18: Shows the measurement of pulmonary veins flow.
- Figure 19: Shows the measurement of Tissue Doppler indexes.
- Figure 20: Shows the patterns of left ventricular (LV) filling as recorded by diastolic Doppler mitral flow velocities.
- Figure 21: Shows the changes in left ventricular mass index with antihypertensive drugs.
- Figure 22: Shows the effect of antihypertensive therapy on blood pressure and left ventricular mass.

- Figure 23: Shows IVS and PWT at end diastole and systole of groups III and I before treatment
- Figure.24: Shows the LVM and LVMI of the groups III and I before treatment.
- Figure.25: Shows RWT of the groups III and I before treatment.
- Figure.26: Shows the transmitral indices of the groups III and I before treatment.
- Figure 27: Shows IVS and PWT at end diastole and systole of groups III and II before treatment.
- Figure.28: shows the LVM and LVMI of the groups III and II before treatment
- Figure.29: Shows the RWT of the groups III and II before treatment
- Figure.30: Shows the transmitral indices of the groups III and II before treatment
- Figure 31: shows IVS and PWT at end diastole and systole of groups I and II before treatment
- Figure.32: Shows the LVM and LVMI of the groups I and II before treatment
- Figure.33: Shows the RWT of the groups I and II before treatment
- Figure.34: Shows the transmitral indices of the groups I and II before treatment
- Figure 35: Shows IVS and PWT at end diastole and systole of groups and I after treatment.
- Figure.36: Shows the LVM and LVMI of the groups III and I after treatment
- Figure.37: Shows the RWT of the groups III and I after treatment

- Figure.38: Shows the transmitral indices of the groups III and I after treatment.
- Figure 39: Shows IVS and PWT at end diastole and systole of groups III and II after treatment.
- Figure.40: Shows the LVM and LVMI of the groups III and II after treatment
- Figure.41: Shows the RWT of the groups III and II after treatment
- Figure.42: Shows the transmitral indices of the groups III and II after treatment
- Figure43 : Shows IVS and PWT at end diastole and systole of groups I and II after treatment
- Figure.44: Shows the LVM and LVMI of the groups I and II after treatment.
- Figure.45: Shows the RWT of the groups I and II after treatment
- Figure.46: Shows the transmitral indices of the groups I and II after treatment
- Figure 47: Shows IVS and PWT at end diastole and systole of subgroup Ia before and after treatment.
- Figure.48 Shows the LVM and LVMI of the subgroup Ia before and after treatment.
- Figure.49 Shows the RWT of the subgroup Ia before and after treatment
- Figure.50: Shows the transmitral indices of the subgroup Ia before and after treatment.
- Figure 51: Shows IVS and PWT at end diastole and systole of subgroup Ib before and after treatment.

- Figure.52: Shows the LVM and LVMI of the subgroup Ib before and after treatment
- Figure.53: Shows the RWT of the subgroup Ib before and after treatment.
- Figure.54: Shows the transmitral indices of the subgroup Ib before and after treatment
- Figure 55: Shows IVS and PWT at end diastole and systole of subgroup IIa before and after treatment.
- Figure.56: Shows the LVM and LVMI of the subgroup IIa before and treatment.
- Figure.57: Shows the RWT of the subgroup IIa before and after treatment.
- Figure.58: Shows the transmitral indices of the subgroup IIa before and after treatment.
- Figure 59: Shows IVS and PWT at end diastole and systole of subgroup IIb before and after treatment.
- Figure.60: Shows the LVM and LVMI of the subgroup IIb before and after treatment.
- Figure.61: Shows the RWT of the subgroup IIb before and after treatment
- Figure 62: Shows the transmitral indices of the subgroup IIb before and after treatment

INTRODUCTION

Hypertension is a leading non-communicable disease. It has been recognized as the most prevalent cardiovascular disease. Adaptation of the left ventricle to systemic hypertension is complex and it is characterized by functional and structural changes in the left ventricle (Casale et al., 1986, Levy et al., 1990). Hypertension may result in left ventricular hypertrophy (LVH) and impairment of diastolic and systolic function (Cuocolo et al., 1990). At some point in the natural history of hypertension, the compensatory increase in LVM ceases to be beneficial and becomes a preclinical disease and an independent risk factor for congestive heart failure, ischemic heart disease, arrhythmia, sudden death, and stroke. Left ventricular hypertrophy is associated with adverse heart consequences, including reduction in systolic and diastolic function, reduced coronary reserve, an increased incidence of arrhythmias (Frohlich et al., 1999, Agabiti-Rosei et al., 2006).

Hypertension is known to be associated with a wide spectrum of LV geometric patterns (**Zabalgaitia et al., 2001**). The hemodynamic predominance between pressure and volume overload plays an important role in the determination and development of various LV geometric patterns. Concentric remodeling tends to occur early in hypertension due to pressure overload but the left ventricular mass is normal while eccentric hypertrophy is due to volume overload with increased left ventricular mass. Various geometric patterns are also influenced significantly by LV systolic function parameters (**de Simone et al., 1999**). Persistent pressure overload in concentric LV geometry with